Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition
Intensive care unit-acquired weakness (ICUAW) occurs in critically ill patients stemming from the critical illness itself, and results in sustained disability long after the ICU stay. Weakness can be attributed to muscle wasting, impaired contractility, neuropathy, and major pathways associated with...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/21/7840 |
id |
doaj-c58cfa8382fc4ecea9e67e18fed415d5 |
---|---|
record_format |
Article |
spelling |
doaj-c58cfa8382fc4ecea9e67e18fed415d52020-11-25T03:53:58ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-10-01217840784010.3390/ijms21217840Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying ConditionHeta Lad0Tyler M. Saumur1Margaret S. Herridge2Claudia C. dos Santos3Sunita Mathur4Jane Batt5Penney M. Gilbert6Institute of Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, CanadaRehabilitation Sciences Institute, University of Toronto, Toronto, ON M5G 2A2, CanadaDivision of Critical Care Medicine, University Health Network, Toronto, ON M5G 2C4, CanadaKeenan Research Center for Biomedical Science, St. Michael’s Unity Health Toronto, Toronto, ON M5B 1T8, CanadaDepartment of Physical Therapy, University of Toronto, Toronto, ON M5G 1V7, CanadaKeenan Research Center for Biomedical Science, St. Michael’s Unity Health Toronto, Toronto, ON M5B 1T8, CanadaInstitute of Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, CanadaIntensive care unit-acquired weakness (ICUAW) occurs in critically ill patients stemming from the critical illness itself, and results in sustained disability long after the ICU stay. Weakness can be attributed to muscle wasting, impaired contractility, neuropathy, and major pathways associated with muscle protein degradation such as the ubiquitin proteasome system and dysregulated autophagy. Furthermore, it is characterized by the preferential loss of myosin, a distinct feature of the condition. While many risk factors for ICUAW have been identified, effective interventions to offset these changes remain elusive. In addition, our understanding of the mechanisms underlying the long-term, sustained weakness observed in a subset of patients after discharge is minimal. Herein, we discuss the various proposed pathways involved in the pathophysiology of ICUAW, with a focus on the mechanisms underpinning skeletal muscle wasting and impaired contractility, and the animal models used to study them. Furthermore, we will explore the contributions of inflammation, steroid use, and paralysis to the development of ICUAW and how it pertains to those with the corona virus disease of 2019 (COVID-19). We then elaborate on interventions tested as a means to offset these decrements in muscle function that occur as a result of critical illness, and we propose new strategies to explore the molecular mechanisms of ICUAW, including serum-related biomarkers and 3D human skeletal muscle culture models.https://www.mdpi.com/1422-0067/21/21/7840muscle atrophycritical illnessintensive care unit-acquired weaknesscritical illness myopathycritical illness polyneuropathyCOVID-19 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Heta Lad Tyler M. Saumur Margaret S. Herridge Claudia C. dos Santos Sunita Mathur Jane Batt Penney M. Gilbert |
spellingShingle |
Heta Lad Tyler M. Saumur Margaret S. Herridge Claudia C. dos Santos Sunita Mathur Jane Batt Penney M. Gilbert Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition International Journal of Molecular Sciences muscle atrophy critical illness intensive care unit-acquired weakness critical illness myopathy critical illness polyneuropathy COVID-19 |
author_facet |
Heta Lad Tyler M. Saumur Margaret S. Herridge Claudia C. dos Santos Sunita Mathur Jane Batt Penney M. Gilbert |
author_sort |
Heta Lad |
title |
Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition |
title_short |
Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition |
title_full |
Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition |
title_fullStr |
Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition |
title_full_unstemmed |
Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition |
title_sort |
intensive care unit-acquired weakness: not just another muscle atrophying condition |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2020-10-01 |
description |
Intensive care unit-acquired weakness (ICUAW) occurs in critically ill patients stemming from the critical illness itself, and results in sustained disability long after the ICU stay. Weakness can be attributed to muscle wasting, impaired contractility, neuropathy, and major pathways associated with muscle protein degradation such as the ubiquitin proteasome system and dysregulated autophagy. Furthermore, it is characterized by the preferential loss of myosin, a distinct feature of the condition. While many risk factors for ICUAW have been identified, effective interventions to offset these changes remain elusive. In addition, our understanding of the mechanisms underlying the long-term, sustained weakness observed in a subset of patients after discharge is minimal. Herein, we discuss the various proposed pathways involved in the pathophysiology of ICUAW, with a focus on the mechanisms underpinning skeletal muscle wasting and impaired contractility, and the animal models used to study them. Furthermore, we will explore the contributions of inflammation, steroid use, and paralysis to the development of ICUAW and how it pertains to those with the corona virus disease of 2019 (COVID-19). We then elaborate on interventions tested as a means to offset these decrements in muscle function that occur as a result of critical illness, and we propose new strategies to explore the molecular mechanisms of ICUAW, including serum-related biomarkers and 3D human skeletal muscle culture models. |
topic |
muscle atrophy critical illness intensive care unit-acquired weakness critical illness myopathy critical illness polyneuropathy COVID-19 |
url |
https://www.mdpi.com/1422-0067/21/21/7840 |
work_keys_str_mv |
AT hetalad intensivecareunitacquiredweaknessnotjustanothermuscleatrophyingcondition AT tylermsaumur intensivecareunitacquiredweaknessnotjustanothermuscleatrophyingcondition AT margaretsherridge intensivecareunitacquiredweaknessnotjustanothermuscleatrophyingcondition AT claudiacdossantos intensivecareunitacquiredweaknessnotjustanothermuscleatrophyingcondition AT sunitamathur intensivecareunitacquiredweaknessnotjustanothermuscleatrophyingcondition AT janebatt intensivecareunitacquiredweaknessnotjustanothermuscleatrophyingcondition AT penneymgilbert intensivecareunitacquiredweaknessnotjustanothermuscleatrophyingcondition |
_version_ |
1724475573634334720 |